Compare ENLV & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENLV | ITRM |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 24.3M |
| IPO Year | 1995 | 2018 |
| Metric | ENLV | ITRM |
|---|---|---|
| Price | $0.83 | $0.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 11.7M | 670.5K |
| Earning Date | 11-28-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $0.35 |
| 52 Week High | $2.10 | $2.10 |
| Indicator | ENLV | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 29.55 |
| Support Level | $0.80 | $0.44 |
| Resistance Level | $0.88 | $0.49 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 6.69 | 8.22 |
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.